New Perspectives on Criteria for the Determination of HCG Trigger Timing in GnRH Antagonist Cycles

Xiaokun Hu, MD, Yingyi Luo, MD, Kejun Huang, MD, Yubing Li, MD, PhD, Yanwen Xu, MD, PhD, Canquan Zhou, MD, PhD, and Qingyun Mai, MD, PhD

INTRODUCTION

The timing of human chorionic gonadotropin (HCG) trigger for final maturation of targeted follicles is determined by many factors, such as follicle diameter, estradiol (E2) and progesterone level, the ratio of peak E2 to the number of oocytes larger than 14 mm, previous controlled ovarian hyperstimulation (COH) protocols, and embryo development. Timing of the onset of luteinization before oocyte retrieval is a terminal act that has an effect on oocyte quality and endometrium receptivity. Patients undergoing gonadotropin-releasing hormone (GnRH) antagonist-controlled cycles exhibit different profiles of follicular recruitment and serum sexual hormone secretion compared with GnRH agonist-controlled cycles.\(^1,2\) Although the criteria used for final oocyte maturation in GnRH antagonist stimulation cycle are as same as those in GnRH-agonist cycles.

The 2-stage pattern of follicular recruitment in antagonist-controlled cycles leads to a more unsynchronized developmental follicle profile than those obtained in agonist-controlled cycles. On the contrary, the GnRH-antagonist blocks pituitary GnRH receptor directly and inhibits follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion without flare-up,\(^3\) which leads to serum E2 level decreasing or maintaining at a platform stage right after several days of GnRH antagonist administration. As a result, the serum estrogen levels are not consistent with the growth of follicles in GnRH antagonist protocol. Thus, such a heterogeneous cohort of follicles and different E2 elevation mode in GnRH antagonist-controlled cycles makes timing of HCG trigger much more complicated and important for the purpose of keeping the balance between maximizing the number of follicles cohort of a mature size and high quality of oocytes.

In most studies, HCG was administered when at least 3 follicles reach a diameter $\geq 17\text{ mm}$\(^4,5\) on ultrasound. As a...
matter of fact, it is currently unclear of the ideal timing of HCG administration for GnRH antagonist in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles. As previously described by Ectors et al,7 a positive relationship between follicular size and the level of cytoplasmatic maturation was observed. Postponing HCG administration and prolonging folliculogenesis to some extent yield relatively more target follicles containing competent oocytes with mature cytoplasm, and may exert positive effects on clinical outcomes.

In all the previous studies, the timing of HCG injection was based on the leading follicle size or simply postponed 1 or 2 days based on the leading follicles size and vague concept of consistent E2 levels regardless of the developmental condition of growing follicles cohort. In this retrospective study, we firstly utilized both the \( \geq 17 \text{ mm} / \geq 10 \text{ mm} \) follicles ratio and the estradiol level per oocyte on the day of HCG (peak E2) to evaluate the follicles cohort developmental condition and determine the timing of HCG administration. These findings may help to clarify the impact of mature follicle proportion and average peak E2 level per oocyte upon the reproductive outcome. We attempted to provide more effective and objective criteria for determining the ideal HCG trigger timing and to obtain high-quality oocytes and higher pregnancy rate in GnRH antagonist-controlled cycles.

**METHODS**

**Patients**

Of the patients who underwent IVF/ICSI-ET at the Reproductive Medicine Center of The First Affiliated Hospital of Sun Yat-sen University from 2011 to 2013, 492 COH cycles with GnRH antagonist protocols reaching fresh embryo-transfer stage were included in the study. The exclusion criteria included endometriol polyps; premature progesterone elevation; preimplantation genetic diagnosis cycles; and nonfresh embryo transfer cycles. This study was approved by the Institutional Review Board of The First Affiliated Hospital of Sun Yat-sen University. All patients provided written, informed consent of assisted reproductive technology (ART) treatment.

**Stimulation Protocols**

All patients underwent GnRH antagonist COH protocols in ART cycles. For the flexible multidose GnRH-antagonist protocol, gonadotropins (Gonal-F; Merck-Serono, Spain) were started on day 2 or 3 of the menstrual cycle. The initial dose of gonadotropin was individualized for each patient according to age, body mass index (BMI), antral follicle count, and/or previous responsiveness to ovarian stimulation. Further dose adjustments were performed on the basis of ovarian response, as evaluated using serum E2 measurement and follicular diameter by transvaginal ultrasound, obtained every 2 or 3 days. The GnRH-antagonist (cetrorelix, 0.25 mg daily, subcutaneously; Serono Laboratories, Geneva, Switzerland) was given an effective dose of 0.25 mg per day subcutaneously in a multiple dose protocol, from the day of mean diameter of dominant follicles larger than 10 mm onwards up to and including the day of HCG administration. Final oocyte maturation by HCG was triggered on the day when at least 3 mature follicles \( \geq 17 \text{ mm} \) were observed by ultrasound. Transvaginal ultrasound guided oocytes retrieval was carried out 36 hours after HCG trigger. Routine IVF/ICSI was then performed as appropriate. The luteal phase was supported with either 40 to 60 mg progesterone intramuscularly (Gestone; Ferring, USA) daily or 600 mg vaginal micronized progesterone soft gel capsules (Utrogestan; Besins Iscovesco, Petah Tikva, Israel) in 3 separate doses daily. Progesterone prolonged releasing vaginal gel (Crinone; Merck Serono, Switzerland) 90 mg daily was supplemented as luteal support as well.

Good-quality embryos were defined as equal-sized, symmetric blastomeres with <10% fragmentation under inspection in a microscope. Fertilization rate was defined as the percentage of fertilized embryos (2PN) in all the mature oocytes. The implantation rate was the proportion of embryos transferred resulting in an intruterine gestational sac. The embryos were transferred after 3 days of ovum pick-up and up to 3 embryos were transfer. Pregnancies were confirmed 3 or 4 weeks after ET, when the serum HCG was elevated. A clinical pregnancy is defined by the presence of 1 or more gestation sacs in the uterus.

**Clinical Data Collection**

A blood test was performed on the 2nd to 5th day of the menstrual cycle before the treatment to determine FSH, LH, and E2 activity. During treatment, patients’ information was documented, including age, duration of gonadotropin administration, total gonadotropin dose, estradiol and progesterone levels on the HCG day, number of oocyte retrieved, and numbers of good quality embryos and transferred embryos. Matured oocyte rate, fertilization rate, implantation rate, clinical pregnancy rate, and live birth rate were calculated.

**Statistical Analysis**

The statistical analyses were performed using SPSS 13 package program (SPSS Inc. Chicago, IL, USA). Categorical data were expressed as number and percentage. Continuous variables were given as mean ± standard deviation if they presented normal distribution. Statistics was given as median and range when the assumption of normality is violated. One-factor analysis of variance (one-way ANOVA) was applied for the comparison between groups for continuous data. Homogeneity of variances was tested and Student–Newman–Keuls (SNK) test was used with equal variances. When the variances were unequal, Tamhanes T2 test was applied as indicated. Pearson Chi-square analysis (\( \chi^2 \) test) was used as well to compare the data among different groups. A \( P \) value of less than 0.05 was considered statistically significant with Bonferroni corrections.

**RESULTS**

A total of 492 consecutive IVF/ICSI cycles were evaluated. Clinical characteristics of the ART cycles in the antagonist group are presented in Table 1. Patients were divided into 3 groups according to their \( \geq 17 \text{ mm} / \geq 10 \text{ mm} \) follicles ratio on the day of HCG administration (Low proportion: \( \geq 17 \text{ mm} / \geq 10 \text{ mm} \) ratio \( \leq 30\% \); Middle proportion: \( \geq 17 \text{ mm} / \geq 10 \text{ mm} \) ratio 30%–60%; High proportion: \( \geq 17 \text{ mm} / \geq 10 \text{ mm} \) ratio \( \geq 60\% \)). No difference existed within the 3 groups with respect to age, basal FSH and LH level, and total gonadotropin dosage in antagonist cycles.

Ovarian response characteristics and reproductive outcomes of the ART cycles in GnRH antagonist group are presented in Table 2 and Figure 1. In Table 2, the number of oocyte retrieved in the low proportion group (9.2 ± 6.3) was significantly higher than those in the middle (7.6 ± 6.0) and high (7.2 ± 6.6) proportion groups. Peak E2 level per oocyte...
retrieved was highest in high proportion group with a large proportion of large follicles. The peak E2 level per oocyte transferred in the low proportion group (242.5 ± 121.8 pg/mL) was significantly lower than those in the middle (285.4 ± 165.4 pg/mL) and high (312.1 ± 194.5 pg/mL) proportion groups. The matured ovum rate in the middle and high proportion group was higher than that in the low proportion group (Low proportion group: 85.1%, Middle proportion group: 87.9%), and statistical significance existed between the low and middle proportion group. Fertilization rate and good quality embryo rate was comparable among the 3 groups. The number of fresh embryos transferred in the low proportion group (2.3 ± 0.7) was meaningfully higher than those in the middle (2.2 ± 0.7) and high (2.0 ± 0.7) proportion groups. The implantation rate of ≥17 mm/≥10 mm groups was 25.8% (54/209) in the high proportion group, which was significantly higher than the low proportion group (17.1%, 54/312.1) and high (312.1 ± 194.5 pg/mL) proportion groups. The implantation rate of ≥17 mm/≥10 mm groups was 30.2% (62/230) in the middle proportion group, and statistical significance existed between the middle and high proportion group. Similarly, the live birth rate exhibited an increasing trend as the ≥17 mm/≥10 mm follicles ratio increases and that of the high proportion group (31.1%, 32/103) was significantly higher than the middle proportion group (19.1%, 44/230).

Patients were further divided into 5 groups according to their peak E2 level/oocyte (Group A: <100 pg/mL per oocyte, Group B: 100–199 pg/mL per oocyte, Group C: 200–299 pg/mL per oocyte, Group D: 300–399 pg/mL per oocyte, Group E ≥400 pg/mL per oocyte). Ovarian response characteristics and reproductive outcomes with different peak E2 level/oocyte groups are summarized in Table 3 and Figure 2. No difference existed within the 5 groups with respect to age, basal FSH and LH level, and total gonadotropin dosage.

The number of oocyte retrieved of 300 to 399 pg/mL per oocyte Group (6.5 ± 4.2) and ≥400 pg/mL per oocyte Group (3.5 ± 2.5) were significantly lower than that of 100 to 199 pg/mL per oocyte Group (10.4 ± 6.9). Matured ovum rate increases as the peak E2 level/oocyte increases, and that of <100 pg/mL per oocyte Group (80.0%, 128/160) was meaningfully lower than those in 200 to 299 pg/mL per oocyte Group (88.2%, 1198/1358, P = 0.003) and 300 to 399 pg/mL per oocyte Group.

### TABLE 1. Clinical Characteristics of GnRH Antagonist ART Cycles

| ≥17 mm/≥10 mm Follicles Ratio (%) | Low Proportion ≤30 | Middle Proportion 30–60 | High Proportion ≥60 | P     |
|----------------------------------|--------------------|-------------------------|---------------------|-------|
| Number of cycles                | 159                | 230                     | 103                 | —     |
| Age (yrs)                       | 35.3 ± 5.4         | 35.4 ± 5.8              | 34.9 ± 6.0          | 0.75  |
| Basal FSH (IU/L)                | 6.5 ± 3.0          | 7.2 ± 3.5               | 7.0 ± 2.7           | 0.13  |
| Basal LH (IU/L)                 | 3.5 ± 3.0          | 3.4 ± 2.4               | 3.3 ± 1.8           | 0.86  |
| Basal E2 (pg/mL)                | 35.6 ± 23.6        | 37.2 ± 20.1             | 39.5 ± 24.1         | 0.27  |
| LOS (d)                         | 8.3 ± 2.1          | 8.6 ± 2.3               | 8.1 ± 2.4           | 0.13  |
| G used (IU)                     | 1728.6 ± 695.6     | 1815.8 ± 822.8          | 1613.7 ± 762.0      | 0.06  |
| Initial G dose (IU)             | 193.9 ± 58.7       | 195.9 ± 61.8            | 181.4 ± 62.6        | 0.10  |

G = gonadotrophin, LOS = length of stimulation (d).

### TABLE 2. Ovarian Response Characteristics and Reproductive Outcomes of GnRH Antagonist ART Cycles

| ≥17 mm/≥10 mm Follicles Ratio (%) | Low Proportion ≤30 | Middle Proportion 30–60 | High Proportion ≥60 | P     |
|----------------------------------|--------------------|-------------------------|---------------------|-------|
| Number of cycles                | 159                | 230                     | 103                 | —     |
| E2-HCG (pg/mL)                  | 1950.8 ± 1244.4    | 1784.2 ± 1283.7         | 1885.4 ± 1490.6    | 0.52  |
| P-HCG (pg/mL)                   | 0.6 ± 0.3          | 0.6 ± 0.3               | 0.6 ± 0.3           | 0.86  |
| NOR (%a)                        | 9.2 ± 6.3          | 7.6 ± 6.0               | 7.2 ± 6.8           | <0.05 |
| E2/oocyte (pg/mL)               | 242.5 ± 121.8      | 285.4 ± 165.4           | 312.1 ± 194.5      | <0.05 |
| MOR (%)                         | 85.1 (1244/1461)   | 89.2 (1552/1739)        | 87.9 (654/744)     | 0.002 |
| FR (%)                          | 73.3 (900/1244)    | 73.6 (1142/1552)        | 75.1 (491/654)     | 0.43  |
| GQ rate (%)                     | 70.0 (630/900)     | 68.3 (780/1142)         | 68.4 (336/491)     | 0.69  |
| NET (%)                         | 2.3 ± 0.7          | 2.2 ± 0.7               | 2.0 ± 0.7          | <0.05 |
| PR (%)                          | 30.2 (48/159)      | 27.0 (62/230)           | 42.7 (44/103)      | 0.015 |
| IR (%)                          | 17.1 (64/375)      | 17.0 (84/495)           | 25.8 (54/209)      | 0.0136 |
| LBR (%)                         | 19.5 (31/159)      | 19.1 (44/230)           | 31.1 (32/103)      | 0.0136 |

E2-HCG = E2 on day of HCG, FR = fertilization rate, GQ = good quality embryo, IR = implantation rate, LBR = live birth rate, MOR = matured oocyte rate, NET = number of embryos transferred, P-HCG = progesterone on day of HCG, PR = pregnancy rate.

aP < 0.05, Values with the same superscript in the same row are significantly different.
The fertilization rate displayed an increasing tendency as the peak E2 level per oocyte increases. The fertilization rate of ≥400 pg/mL per oocyte Group (81.8%, 202/247) was significantly higher than those in <100 pg/mL per oocyte Group (66.4%, 85/128, P = 0.001), 100 to 199 pg/mL per oocyte Group (72.9%, 1032/1416, P = 0.003), and 300 to 399 pg/mL per oocyte Group (70.1%, 323/461, P = 0.001).

The good quality embryos rate of 300 to 399 pg/mL per oocyte Group (76.2%) and ≥400 pg/mL per oocyte Group (84.2%) were significantly higher than 100 to 199 pg/mL per oocyte Group (64.9%) and 200 to 299 pg/mL per oocyte (67.3%). However, the number of fresh embryos transferred of 100 to 199 pg/mL per oocyte Group (2.3 ± 0.7) and 200 to 299 pg/mL per oocyte (2.3 ± 0.7) were significantly more than that of ≥400 pg/mL per oocyte Group (1.8 ± 0.8). In addition, the implantation, pregnancy, and live birth rate were higher in 100 to 199 pg/mL per oocyte Group, 200 to 299 pg/mL per oocyte group, and 300 to 399 pg/mL per oocyte group than <100 pg/mL per oocyte Group and ≥400 pg/mL per oocyte Group (Group A: 11.1%/16.7%/16.7%, Group B: 20.5%/38.6%/25.3%, Group C: 20.7%/34.8%/26.1%, Group D: 18.2%/29.1%/19.0%, Group E: 11.4%/14.5%/9.2%). Pregnancy rate of 100 to 199 pg/mL per oocyte Group and 200 to 299 pg/mL per oocyte Group were significantly higher than that of ≥400 pg/mL per oocyte Group as shown in Figure 2. Significant difference also existed between <100 pg/mL per oocyte Group and 100 to 199 pg/mL per oocyte Group. The live birth rate of ≥400 pg/mL per oocyte Group was significantly lower than that of 100 to 199 pg/mL per oocyte Group and 200 to 299 pg/mL per oocyte Group.

**DISCUSSION**

This is the first study to use quantification criteria to evaluate the mature status of follicles cohort and choose the ideal timing of HCG trigger in GnRH antagonist protocol. The mature follicles proportion and elevated E2 level per oocyte
were used to evaluate the developmental condition of numerous follicles in various sizes. In this retrospective study, comparison of implantation and pregnancy rate among different proportion of mature follicle group and different level of peak E2/oocyte was made to find out an ideal timing of HCG trigger. The higher proportion of mature follicle within 100–399 pg/mL E2 level per oocyte on the HCG day was associated with a higher pregnancy and implantation rate among different proportion of mature follicles group and different level of peak E2/oocyte to analyze their effects on IVF outcomes in patients undergoing GnRH-antagonist COH protocols and try to provide more effective and objective criteria for determining the ideal HCG trigger timing than the theoretically proposed fixed criterion of ‘‘at least 3 follicles are more than 17 mm of diameter.’’

Several studies had reported that postponing HCG administration for inducing final follicular maturation by 1 to 2 days did not influence reproductive outcome. The main point we need to focus on is the whole developmental condition of growing follicles cohort other than to consider whenever the HCGs were injected on the day on which at least 3 follicles reached 17 mm or 2 days later.

Kolbianakis et al.9 reported that in GnRH antagonist cycles, the proportion of follicles with diameters 11 to 15 mm, 15 to 17 mm, and 17 mm or more were 35%, 15%, and 30%, respectively, on the day of HCG administration. These follicles of different developmental stage produced different competent oocytes. It has been well established in several domestic and model species that the proportion of competent oocytes increases with follicular size. Many studies have demonstrated that follicular size is positively related to the development, the purpose of COH is providing high-quality oocytes with nuclear and cytoplasmatic maturation. While how to evaluate oocytes’ maturation status in developing follicles cohort? As we know, follicle diameter and E2 level are 2 useful clinical indexes used to judge whether the oocyte in growing follicles is mature or not. Thus, we selected 2 objective criteria including mature follicle proportion and average peak E2 level per oocyte to analyze their effects on IVF outcomes in patients undergoing GnRH-antagonist COH protocols and try to provide more effective and objective criteria for determining the ideal HCG trigger timing than the theoretically proposed fixed criteria of ‘‘at least 3 follicles are more than 17 mm of diameter.’’

### TABLE 3. Ovarian Response Characteristics and Reproductive Outcomes With Different Peak E2 Level/Oocyte in GnRH Antagonist Group

| Peak E2 Level/Oocyte | Group A | Group B | Group C | Group D | Group E | P |
|----------------------|---------|---------|---------|---------|---------|---|
| Number of cycles     | <100 pg/mL | 158 | 161 | 79 | 76 | — |
| Age (yrs)            | 36.7 ± 7.1 | 35.1 ± 5.3 | 34.7 ± 6.1 | 34.8 ± 5.6 | 36.9 ± 5.2 | 0.27 |
| Basal FSH (IU/L)     | 6.9 ± 2.4 | 6.6 ± 3.0 | 7.0 ± 3.4 | 7.1 ± 3.3 | 7.4 ± 3.2 | 0.69 |
| Basal LH (IU/L)      | 2.4 ± 1.3 | 3.2 ± 2.0 | 3.6 ± 3.3 | 3.5 ± 1.9 | 3.6 ± 2.5 | 0.08 |
| Basal E2 (pg/mL)     | 34.1 ± 23.7 | 34.8 ± 19.8 | 35.2 ± 19.4 | 38.7 ± 19.2 | 45.2 ± 31.4 | 0.07 |
| LOS (d)              | 8.4 ± 2.5 | 8.4 ± 2.0 | 8.4 ± 2.3 | 8.4 ± 2.4 | 8.4 ± 2.5 | 1.00 |
| G used (IU)          | 1804.2 ± 1010.0 | 1748.6 ± 743.4 | 1727.0 ± 694.0 | 1728.9 ± 820.2 | 1780.4 ± 893.1 | 0.99 |
| Initial G dose (IU)  | 191.7 ± 69.1 | 195.7 ± 63.3 | 191.6 ± 57.3 | 188.3 ± 64.6 | 190.5 ± 59.9 | 0.97 |
| E2-HCG (pg/mL)       | 699.2 ± 679.8 | 1652.4 ± 1154.6 | 2029.7 ± 1431.7 | 2247.7 ± 1439.1 | 1798.9 ± 1193.4 | 0.05 |
| P-HCG (pg/mL)        | 0.4 ± 0.2 | 0.5 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.5 ± 0.3 | 0.053 |
| NOR                  | 8.9 ± 7.9 | 10.4 ± 6.9<sup>a</sup> | 8.4 ± 6.2 | 6.5 ± 4.2<sup>a</sup> | 3.5 ± 2.5<sup>a</sup> | <0.05 |
| E2/oocyte (pg/mL)<sup>1</sup> | 77.5 ± 17.0 | 157.5 ± 28.2 | 246.7 ± 28.2 | 344.1 ± 28.9 | 568.0 ± 184.9 | <0.05 |
| MOR (%)              | 80.0<sup>a</sup> | 86.0<sup>a</sup> | 88.2<sup>a</sup> | 89.3<sup>a</sup> | 93.9<sup>a</sup> | 0.000 |
| PR (%)               | 66.4<sup>a</sup> | 72.9<sup>a</sup> | 74.4<sup>a</sup> | 70.1<sup>a</sup> | 81.8<sup>a,b</sup> | 0.004 |
| GQE rate (%)         | 70.6 | 64.9<sup>a</sup> | 67.3<sup>a</sup> | 76.2<sup>a</sup> | 84.2<sup>a,b</sup> | 0.000 |
| NET                  | 2.0 ± 0.9 | 2.3 ± 0.7<sup>a</sup> | 2.3 ± 0.7<sup>a</sup> | 2.2 ± 0.7<sup>a</sup> | 1.8 ± 0.8<sup>a</sup> | <0.05 |
| PR (%)               | 16.7 (3/18)<sup>a</sup> | 38.6 (61/158)<sup>a</sup> | 34.8 (56/161)<sup>a</sup> | 29.1 (23/79)<sup>a</sup> | 14.5 (11/76)<sup>a</sup> | 0.002 |
| IR (%)               | 11.1 (4/36) | 20.5 (76/371) | 20.7 (75/362) | 18.2 (31/170) | 11.4 (16/140) | 0.09 |
| IR (%)               | 16.7 (3/18) | 25.3 (40/158)<sup>a</sup> | 26.1 (42/161)<sup>a</sup> | 19.0 (15/79)<sup>a</sup> | 9.2 (7/76)<sup>a</sup> | 0.03 |

E2-HCG = E2 on day of HCG, FR = fertilization rate, G = gonadotrophin, GQE = good quality embryo, IR = implantation rate, LBR = live birth rate, LOS = length of stimulation (d), MOR = mature oocyte rate, NET = number of embryos transferred, NOR = number of oocyte retrieved, P-HCG = progesterone on day of HCG, PR = pregnancy rate.

P < 0.05; there were significant differences compared with the other 4 groups.

P < 0.05; there were significant differences in all the 5 groups.

<sup>a</sup> <sup>b</sup> p < 0.05; Values with the same superscript in the same row are significantly different.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
The ability of oocyte to be fertilized and to develop, and those oocytes from large follicles tend to develop high-quality embryos.\textsuperscript{7,11,12} The difference in pregnancy and implantation rate among 3 groups indicates that embryos originating from different size group follicles might have different long-term developmental competence.

In contrast to the result of present studies, the number of oocyte retrieved in the low proportion group was significantly higher than the other 2 groups, while the mature oocyte rate is lowest in the low proportion group. The fertilization rate and good quality embryo rate was comparable among the 3 groups. The oocytes in some oversize follicles might either degenerate or decrease in quality, which made the oocyte retrieval decreasing. On the contrary, a premature harvest yields oocytes that are not yet cytoplasmically mature even though they readily undergo nuclear maturation and fertilization, which has a detrimental effect on embryo development.\textsuperscript{13}

In agreement with the result of present study, as the ratio of \geq 17 \text{ mm} / \geq 10 \text{ mm} follicles increases, peak serum E2 level and peak E2 level per oocyte retrieved were increased. The increase of E2 level is not always consistent with the enlarging follicle diameter in GnRH antagonist cycle. Fleming\textsuperscript{2} demonstrated that the rate of increase of estradiol concentration was reduced at GnRH antagonist administration, and in some cases, the concentration may even show a short-term decrease. Akman et al\textsuperscript{14} observed that serum E2 levels were significantly lower in the antagonist group on cycle day 2, HCG day, and oocyte retrieval day than the agonist groups. Lindheim and Morales\textsuperscript{15} found a decline in serum estradiol in almost one-third of the cycles after GnRH antagonist administration as well. All the previous studies indicated that we need another range of E2 level to evaluate the maturation of follicles in GnRH antagonist cycle. In the latter stage of COH, multiple follicles with various sizes are present and contributing to a different degree to E2 production. Moreover, the dynamics of LH secretion are different between the GnRH agonist and antagonist cycle.\textsuperscript{2} It makes the concept of E2 level per follicle in GnRH antagonist stimulated cycles complex and vague. Orvieto et al\textsuperscript{16} suggested that patients undergoing GnRH antagonist protocol should reach a peak E2 level/oocyte within

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2}
\caption{Pregnancy outcomes of GnRH antagonist cycles in different peak E2 level/oocyte groups. \textsuperscript{a, b, c} \textit{P} < 0.05. Values with the same superscript with respect to pregnancy rate, implantation rate, and live birth rate, respectively, are significantly different. The clinical pregnancy rate 100 to 199 pg/mL per oocyte Group: 38.6\% vs. \geq 400 pg/mL per oocyte Group: 14.5\%; \textit{P} = 0.000; 200 to 299 pg/mL per oocyte Group: 34.8\% vs. \geq 400 pg/mL per oocyte Group: 14.5\%; \textit{P} = 0.001; \leq 100 pg/mL per oocyte Group: 16.7\% vs. 100 to 199 pg/mL per oocyte Group: 38.6\%; \textit{P} = 0.002. The live birth rate 100 to 199 pg/mL per oocyte Group: 25.3\% vs. \geq 400 pg/mL per oocyte Group: 9.2\%; \textit{P} = 0.004; 200 to 299 pg/mL per oocyte Group: 26.1\% vs. \geq 400 pg/mL per oocyte Group: 9.2\%; \textit{P} = 0.003.}
\end{figure}
the 100 to 200 pg/mL range in order to gain a higher pregnancy rate.

In our retrospective study, the number of oocyte retrieved was significantly lowest when average peak E2 level/oocyte was higher than 400 pg/mL. The lost oocyte in ≥400 pg/mL per oocyte group may be partially explained by the concomitant high intrafollicular level of androgen, which has a deleterious effect on follicular maturation and development, thus enhance ovarian granulose cell apoptosis or, alternatively, by a high proportion of degenerative oocytes.

Our findings showed that when the proportion of >17 mm follicles is more than 60%, the patients can get a higher pregnancy and implantation rate in GnRH antagonist protocol. At the same time, patients should keep the peak E2 level/oocyte within a range of 100–399 pg/mL in order to gain better IVF outcome, lower pregnancy, and implantation rates and could be expected if the range is exceeded. While for the patient with E2 level/oocyte greater than 100 pg/mL, all embryos should be cryopreserved for frozen-thawed embryos transfer. The peak E2 level/oocyte less than 100 pg/mL indicates that the oocytes are immature. The low pregnancy and implantation rate might be due to the less competent oocytes with immature cytoplasm. Even though they readily undergo nuclear maturation, it has a detrimental effect on fertilization and embryo development.

Our retrospective study included its retrospective nature and the small number of patients in the different groups. In the future, it may be useful to plan prospective randomized studies with an equal number of patients and to assess the proper timing in GnRH antagonist protocols. It may also be useful to plan prospective randomized trials with recombinant follicle stimulating hormone and GnRH antagonist administration on endometrial receptivity.21,22 So that, when the peak E2 level per oocyte exceed 400 pg/mL, patients should avoid fresh embryo transfer and all embryos should be cryopreserved for frozen-thawed embryos transfer. The peak E2 level/oocyte exceeding 400 pg/mL or less than 100 pg/mL. The consistent E2 levels are believed to indicate follicular health. Accordingly, Yang et al20 found that IVF cycles using GnRH-agonist protocol with an elevated peak E2 level/oocyte exceeding 350 pg/mL/oocyte correlated with lower pregnancy and implantation rates. In our study, it should be noted that although the pregnancy and implantation rate were lowest in ≥400 pg/mL per oocyte group, the mature ovum rate, fertilization rate, and high-quality embryos rate were highest. The low implantation and pregnancy rate may be due to the effect of supraphysiological serum estradiol concentrations and GnRH antagonist administration on endometrial receptivity.21,22 So that, when the peak E2 level per oocyte exceed 400 pg/mL, patients should avoid fresh embryo transfer and all embryos should be cryopreserved for frozen-thawed embryos transfer. The peak E2 level/oocyte less than 100 pg/mL indicates that the oocytes are immature. The low pregnancy and implantation rate might be due to the less competent oocytes with immature cytoplasm. Even though they readily undergo nuclear maturation, it has a detrimental effect on fertilization and embryo development.

CONCLUSION

As far as we know, this is the first study to investigate both the proportion of mature follicles and the ratio of peak E2 to the number of oocytes retrieved to clarify the proper timing of HCG administration in GnRH-antagonist COH protocols. Patients with the proportion of mature follicle reaching 60% on the day of HCG trigger and peak estradiol/oocyte level within 100–399 pg/mL range can get a better pregnancy and implantation rate in GnRH antagonist protocol. Lower pregnancy rate could be expected whenever E2/oocyte ratio exceeds 400 pg/mL per oocyte in fresh embryo transfer GnRH antagonist cycles. We provide new and objective criteria to determine more appropriate timing of HCG trigger for high-quality oocytes and higher pregnancy rate in GnRH-antagonist COH protocols. It is also the first time to clarify relationship between the E2 level per oocyte and mature follicles proportion, which offers new clue to evaluate cytoplasmic maturation status of oocytes and helps clinicians determine optimal HCG trigger timing in GnRH-antagonist COH protocols.

ACKNOWLEDGMENTS

The authors thank Mrs Wan Saihong for her help with inputting the data for analysis. We also thank Dr Qiong Wang, Dr Jie Li, Dr Yiping Zhong, and Dr Jianping Ou for their help in clinical works.

REFERENCES

1. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod. 2007;22:2805–2813.
2. Fleming R. Monitoring during gonadotrophin-releasing hormone antagonist protocols. Hum Fertil. 2002;5:G19–G24.
3. Al-Imany HG, Yousef MA, Abouhargh M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;5:CD001750.
4. Borm G, Mannhaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod. 2000;15:1409–1408.
5. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. 2001;16:644–651.
6. Kyrrou D, Al-Azemi M, Papanikolaou EG, et al. The relationship of premature progesterone rise with serum estradiol levels and number of follicles in GnRH antagonist recombinant FSH-stimulated cycles. Eur J Obstet Gynecol Reprod Biol. 2012;162:165–168.
7. Ectors FJ, Vanderzwalmen P, Van Hoeck J, et al. Relationship of human follicular diameter with oocyte recovery and maturity at the time of oocyte retrieval, fertilization, cleavage, and embryo quality in in vitro fertilization cycles using GnRH antagonist protocols.
13. Chian RC, Lim JH, Tan SL. State of the art in in-vitro oocyte maturation. *Curr Opin Obstet Gynecol.* 2004;16:211–219.

14. Akman MA, Erden HF, Tosun SB, et al. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. *Hum Reprod.* 2001;16:868–870.

15. Lindheim SR, Morales AJ. GnRH antagonists followed by a decline in serum estradiol results in adverse outcomes in donor oocyte cycles. *Hum Reprod.* 2003;18:2048–2051.

16. Orvieto R, Zohav E, Scharf S, et al. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization. *Gynecol Endocrinol.* 2007;23:72–75.

17. Billig H, Furuta I, Hsueh AJ. Estrogens inhibit and androgens enhance ovarian granulosa cell apoptosis. *Endocrinology.* 1993;133:2204–2212.

18. Hillier SG, Reichert LE Jr, Van Hall EV. Control of preovulatory follicular estrogen biosynthesis in the human ovary. *J Clin Endocrinol Metab.* 1981;52:847–856.

19. van Dessel HJ, Schipper I, Pache TD, et al. Normal human follicle development: an evaluation of correlations with oestradiol, androstenedione and progesterone levels in individual follicles. *Clin Endocrinol.* 1996;44:191–198.

20. Yang JH, Chen HF, Lien YR, et al. Elevated E2: oocyte ratio in women undergoing IVF and tubal ET. Correlation with a decrease in the implantation rate. *J Reprod Med.* 2001;46:434–438.

21. Sauer Ramirez JL, Hernandez Perez O. [Endometrial changes caused by induction of ovarian hyperstimulation which affect the process of embryo implantation]. *Ginecol Obstet Mexico.* 1994;62:415–418.

22. Prapas N, Tavaniotou A, Panagiotidis Y, et al. GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial. *Reprod Biomed Online.* 2009;18:276–281.